Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | Advances in mHSPC treatment strategies: PARP inhibitors, PSMA-targeting & more

Andrew Armstrong • 1 Jun 2025
ASCO 2025
Genitourinary Cancer Prostate Cancer Abiraterone Enzalutamide Niraparib Talazoparib
AMPLITUDE ARCHES EvoPAR-Prostate01 TALAPRO-3

Andrew Armstrong, MD, MS, Duke Cancer Institute, Durham, NC, shares his insights on the evolving therapeutic landscape of metastatic hormone-sensitive prostate cancer (mHSPC), emphasizing key changes in standard treatment and the emergence of novel therapeutics. He highlights promising recent and ongoing trials that are investigating the use of PARP inhibitors, PSMA radioligand therapy, EZH2 inhibition, and metastatic-directed therapy (MTD) to improve mHSPC management. This interview took place at the 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Andrew Armstrong

Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
TulmiSTAR-01: tulmimetostat with luxdegalutamide in mCRPC
1:16
TulmiSTAR-01: tulmimetostat with luxdegalutamide in mCRPC
Andrew Armstrong • 26 Feb 2026
Implementing PCWG4 guidance to refine endpoints in prostate cancer
1:23
Implementing PCWG4 guidance to refine endpoints in prostate cancer
Andrew Armstrong • 26 Feb 2026

Related Videos

Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals